JACC. Case reports · 2026
Dasatinib-Induced Pulmonary Arterial Hypertension.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Musthafa Hafeesa Nimisha, Mufti Gulbadin, Sivadasanpillai Harikrishnan
Аннотация
INTRODUCTION: Pulmonary arterial hypertension (PAH) is a serious complication of dasatinib, used for the treatment of chronic myeloid leukemia. Although drug-induced PAH is a recognized entity, the timeline for onset and the degree of recovery on drug withdrawal remain poorly defined.
CASE SUMMARY: This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months.
CONCLUSIONS: Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.
CASE SUMMARY: This review includes a series of 5 cases of dasatinib-induced PAH, in which PAH partially or fully reversed on discontinuation of the drug. All cases had documented normal cardiac status at baseline and developed PAH within 12-24 months of initiation. Three cases required pulmonary vasodilators in addition to discontinuation of the drug. The median time to resolution of PAH was 2 (2-4.5) months.
CONCLUSIONS: Dasatinib-induced PAH is a reversible yet serious condition, which mandates regular screening of patients for early recognition of the condition. Larger series with longer follow-up are mandated for better understanding of the factors associated with the risks and severity of the condition.